Stada suffers on weakness in Germany; Pfizer nabs eponymous Twitter handle; Otsuka registers first U.S. lobbyists;

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Germany's Stada saw shares fall as lagging results in its home market dragged earnings short of analyst estimates. Report

> Pfizer ($PFE) finally took over the @pfizer handle on Twitter; when it first joined the social media network in 2009, another user had already grabbed the name. Report

> Japan's Otsuka Pharmaceutical tapped two lobbyists as its first in the U.S. capital. Report

> Reckitt Benckiser rolled out its heartburn drug Gaviscon nationally in India. Report

> Baxter International ($BAX) announced a quarterly dividend of $0.49 per share, bringing its annualized dividend to $1.96. Report

> Drug distributor Celesio posted a 5.5% decline in profits on a price war in its home market. Report

> U.S.-based Life Technologies ($LIFE) cut the ribbon on its new office in Seoul, Korea, with plans to invest in growth in that market. Report

Medical Device News

@FierceMedDev: Syneron fattens revenue with slim-down, North American focus. More | Follow @FierceMedDev

@MarkHFierce: The latest weekly edition of FierceDiagnostics is ready for viewing. Check it out, and spread the word. Issue | Follow @MarkHFierce

@MichaelGFierce: Brain tumors succumb to drugs delivered via bone scaffold. News | Follow @MichaelGFierce

> Boston Scientific sets FDA date for closely watched Watchman. Article

> FDA slaps 'deadly' tag on Atossa's cancer Dx recall. Piece

> Syneron fattens revenue with slim-down, North American focus. More

> Myriad's melanoma Dx launch continues aggressive test rollout. Item

Biotech News

@FierceBiotech: GeNO, uniQure look to leap through biotech IPO window in Q4 rush. More | Follow @FierceBiotech

@JohnCFierce: True, first wave of cancer vaccines has been a disappointment. Good reason for skepticism as well--but that's almost always the case. | Follow @JohnCFierce

@DamianFierce: Updated: Roche taps immatics in immunotherapy cancer R&D deal worth up to $1B. More | Follow @DamianFierce

@EmilyMFierce: Yale study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. News | Follow @EmilyMFierce

> Troubled Transcept ditching 43% of staff with eye on getting bought. Article

> Merck KGaA adds $232M China R&D partnership to growing cancer drug collaboration. More

> Helpful regulators, blockbuster drug strategy deliver a crop of major breakthroughs. Item

Drug Delivery News

> MedImmune taps Unilife for wearable biologic injectable tech. Report

> DNA-delivering patch spurs bone growth. Story

> Study: Once-toxic peptide may deliver large molecules. Article

> Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia. More

> Brain tumors succumb to drugs delivered via bone scaffold. Report

> Carbon nanotubes sneak drugs past gatekeeper proteins. Item

Diagnostics News

> Response Genetics sees disappointing Q3 as Dx revenue declines. Story

> VolitionRx, heartened by early data, shifts to multiple colorectal cancer Dx studies. Article

> Ex-Sequenom CEO seeks compensation in wake of scandal-related firing. More

> Oxford Immunotec's Dx milestones could supercharge IPO. Report

> Myriad gears up for melanoma test rollout. Story

> Myriad's signature BRCA test continues to generate lion's share of revenue. Item

Biomarkers News

> Study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. Story

> J&J, nonprofits fund new research into links between Down syndrome, Alzheimer's. More

> Protein in damaged tissue could be biomarker for muscular dystrophy. Article

> Biomarker could predict preeclampsia in pregnant women. Report

> U.K. crew eyes biomarker as flag for atrial fibrillation complications. Story

> Researchers flag protein biomarker for aggressive oral cancer. Item

And Finally... Employees at Boehringer Ingelheim in the U.K. are running two beehives in hopes of selling honey to benefit charity. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.